Synergistic effects of piperlongumine and gemcitabine against KRAS mutant lung cancer.

Tumori
Wu YeGuangyue Qin

Abstract

To determine the combined efficacy of piperlongumine and gemcitabine for treatment of KRAS mutant lung cancer. The cell growth inhibition of piperlongumine, gemcitabine, and piperlongumine plus gemcitabine was measured by Cell Counting Kit‑8 assay and the combination index was calculated. In addition, the combined effects of piperlongumine and gemcitabine on cell apoptosis, reactive oxygen species (ROS) contents, and microtubule-associated protein 1 light chain 3B (LC3B) expression were examined. Piperlongumine increased ROS contents and LC3B-II expression. Following the combined treatment with piperlongumine and 10 mM N-acetyl-L-cysteine (NAC), intracellular ROS and cell viability returned to normal levels, and the expression of LC3B-II decreased to the predose level. Gemcitabine also induced cell apoptosis, increased ROS contents, and LC3B-II expression. The combination of piperlongumine with gemcitabine exhibited a synergetic anticancer activity with the combination index <1. The combined application of gemcitabine and piperlongumine yielded synergistic effects on cell apoptosis, but failed to synergistically increase ROS levels and LC3B-II expression. Combination therapy with piperlongumine and gemcitabine is a promising tr...Continue Reading

References

Jan 6, 2005·The Oncologist·Bea PauwelsJan B Vermorken
Sep 18, 2012·Molecular Pharmaceutics·Elodie MoysanJean-Pierre Benoit
Apr 23, 2013·Toxicology in Vitro : an International Journal Published in Association with BIBRA·H RandhawaK M Reindl
Oct 5, 2013·Cell Death & Disease·Y WangZ-X Xu
Aug 2, 2014·European Journal of Pharmacology·Lucas de Sousa Cavalcante, Gisele Monteiro
Jun 6, 2016·Current Pharmaceutical Design·Sahdeo Prasad, Amit K Tyagi
Sep 8, 2016·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Marco B E SchaafKasper M A Rouschop
Sep 16, 2017·Apoptosis : an International Journal on Programmed Cell Death·Sunisa ThongsomChutima Talabnin
Mar 20, 2018·Journal of Experimental & Clinical Cancer Research : CR·Meng-Shih WengMing-Hsien Chien
Mar 27, 2018·Biotechnology and Applied Biochemistry·Jinhui ZhuJiale Zhou
Jun 6, 2018·Frontiers in Physiology·Zewen LiuLi Zuo
Jul 15, 2018·European Journal of Medicinal Chemistry·Kamil PiskaElżbieta Pękala
Nov 7, 2018·Anticancer Research·Fernanda DA Silva MachadoMariana Roesch-Ely
Aug 14, 2019·Nature Reviews. Cancer·Ferdinandos Skoulidis, John V Heymach
Nov 2, 2019·Nature·Jude CanonJ Russell Lipford
Feb 6, 2020·Translational Lung Cancer Research·Sutima LuangdilokVirote Sriuranpong
Feb 6, 2020·Cancer Treatment Reviews·Misako NagasakaAsfar S Azmi

❮ Previous
Next ❯

Citations

May 1, 2021·European Journal of Medicinal Chemistry·Peng ZhuYong Ling

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis